Summit Therapeutics Inc. today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in first-line metastatic colorectal cancer (mCRC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results